



Chronic Lymphocytic Leukemia: Therapy and Outcome

Guest Editor:

Dr. Andrea Visentin

Department of Medicine-DIMED,
Hematology Unit, University of
Padova, 35128 Padova, Italy

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editor

Dear Colleagues,

In the last 15 years, our understanding of chronic lymphocytic leukemia has been revolutionized thanks to significant insights into the molecular biology of the disease and the interplay between neoplastic cells and the surrounding microenvironment. The identification of molecules which are pivotal to the survival of malignant cells has allowed us to develop targeted therapies (monoclonal antibodies, kinase inhibitors and BH3-mimetics) that have become the cornerstone of chronic lymphocytic leukemia treatment.

Despite these advances, the disease remains incurable and hypogammaglobulinemia, infections, and second primary malignancies still impinge upon patients' quality of life.

For this Special Issue, we are pleased to invite you to submit original research articles and reviews on any aspect of chronic lymphocytic leukemia are welcome. Research areas may include (but are not limited to) diagnostic pitfall, prognostic factor, predictive factors, critical signaling pathways, comorbidities, targeted therapies, management of kinase inhibitors, Richter syndrome, supporting therapies, and quality of life.

We look forward to receiving your contributions.

